AT1 RECEPTOR AUTOANTIBODIES MEDIATE EFFECTS OF METABOLIC SYNDROME ON DOPAMINERGIC VULNERABILITY.
Egile Nagusiak: | Ana Isabel Rodríguez Pérez, María A Pedrosa, Carmen M Labandeira, Rita Valenzuela, Aloia Quijano, Mariña Sanchez-Andrade, Juan Antonio Suárez-Quintanilla, Jose Lanciego, José Luis Labandeira-García |
---|---|
Formatua: | Artikulua |
Hizkuntza: | English |
Argitaratua: |
Elsevier
2023-10-01
|
Saila: | IBRO Neuroscience Reports |
Sarrera elektronikoa: | http://www.sciencedirect.com/science/article/pii/S2667242123010126 |
Antzeko izenburuak
-
ANGIOTENSIN TYPE-1 RECEPTOR AND ACE2 AUTOANTIBODIES IN PARKINSON´S DISEASE
nork: Ana Isabel Rodríguez Pérez, et al.
Argitaratua: (2023-10-01) -
Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease
nork: Carmen M. Labandeira, et al.
Argitaratua: (2022-06-01) -
Angiotensin type-1 receptor autoantibodies promote alpha-synuclein aggregation in dopaminergic neurons
nork: Lucia Lage, et al.
Argitaratua: (2024-11-01) -
Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment
nork: Jose L. Labandeira-Garcia, et al.
Argitaratua: (2022-02-01) -
Brain renin-angiotensin system and dopaminergic cell vulnerability
nork: Jose L Labandeira-Garcia, et al.
Argitaratua: (2014-07-01)